Menu
Search
|

Menu

Close
X

Vaxart Inc VXRT.OQ (NASDAQ Stock Exchange Capital Market)

2.52 USD
-0.05 (-1.95%)
As of Nov 14
chart
Previous Close 2.57
Open 2.56
Volume 5,626
3m Avg Volume 63,207
Today’s High 2.59
Today’s Low 2.41
52 Week High 9.46
52 Week Low 2.41
Shares Outstanding (mil) 7.14
Market Capitalization (mil) 18.10
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
9
FY16
9
FY15
25
EPS (USD)
FY18
-0.870
FY17
-8.369
FY16
-7.203
FY15
-5.812
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
6.14
22.95
Price to Book (MRQ)
vs sector
0.81
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
20.20
15.47
LT Debt to Equity (MRQ)
vs sector
12.06
11.13
Return on Investment (TTM)
vs sector
-15.96
13.00
Return on Equity (TTM)
vs sector
-44.12
14.69

EXECUTIVE LEADERSHIP

Wouter Latour
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
John Harland
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Sean Tucker
Chief Scientific Officer, Since 2018
Salary: --
Bonus: --
David Taylor
Chief Medical Officer, Since 2018
Salary: --
Bonus: --
Michael Finney
Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

395 Oyster Point Blvd Ste 405
SOUTH SAN FRANCISCO   CA   94080-1995

Phone: +1650.5503500

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

SPONSORED STORIES